GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003243429 | Skin | cSCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 80/4864 | 134/18723 | 1.54e-16 | 1.49e-14 | 80 |
GO:200005829 | Skin | cSCC | regulation of ubiquitin-dependent protein catabolic process | 92/4864 | 164/18723 | 2.30e-16 | 2.12e-14 | 92 |
GO:004586229 | Skin | cSCC | positive regulation of proteolysis | 169/4864 | 372/18723 | 2.43e-16 | 2.21e-14 | 169 |
GO:190285016 | Skin | cSCC | microtubule cytoskeleton organization involved in mitosis | 85/4864 | 147/18723 | 2.66e-16 | 2.39e-14 | 85 |
GO:0032386110 | Skin | cSCC | regulation of intracellular transport | 156/4864 | 337/18723 | 4.48e-16 | 3.96e-14 | 156 |
GO:000705215 | Skin | cSCC | mitotic spindle organization | 73/4864 | 120/18723 | 7.81e-16 | 6.80e-14 | 73 |
GO:003304417 | Skin | cSCC | regulation of chromosome organization | 100/4864 | 187/18723 | 8.97e-16 | 7.70e-14 | 100 |
GO:0045727112 | Skin | cSCC | positive regulation of translation | 79/4864 | 136/18723 | 2.09e-15 | 1.75e-13 | 79 |
GO:0006401111 | Skin | cSCC | RNA catabolic process | 133/4864 | 278/18723 | 2.71e-15 | 2.23e-13 | 133 |
GO:003315724 | Skin | cSCC | regulation of intracellular protein transport | 115/4864 | 229/18723 | 2.74e-15 | 2.23e-13 | 115 |
GO:000683927 | Skin | cSCC | mitochondrial transport | 124/4864 | 254/18723 | 3.54e-15 | 2.81e-13 | 124 |
GO:003425026 | Skin | cSCC | positive regulation of cellular amide metabolic process | 89/4864 | 162/18723 | 3.95e-15 | 3.06e-13 | 89 |
GO:007058525 | Skin | cSCC | protein localization to mitochondrion | 74/4864 | 125/18723 | 3.95e-15 | 3.06e-13 | 74 |
GO:000989628 | Skin | cSCC | positive regulation of catabolic process | 206/4864 | 492/18723 | 6.06e-15 | 4.64e-13 | 206 |
GO:0019079112 | Skin | cSCC | viral genome replication | 76/4864 | 131/18723 | 7.80e-15 | 5.76e-13 | 76 |
GO:0006402111 | Skin | cSCC | mRNA catabolic process | 115/4864 | 232/18723 | 9.01e-15 | 6.57e-13 | 115 |
GO:007265525 | Skin | cSCC | establishment of protein localization to mitochondrion | 71/4864 | 120/18723 | 1.48e-14 | 1.04e-12 | 71 |
GO:000705115 | Skin | cSCC | spindle organization | 96/4864 | 184/18723 | 2.59e-14 | 1.77e-12 | 96 |
GO:003133128 | Skin | cSCC | positive regulation of cellular catabolic process | 182/4864 | 427/18723 | 3.29e-14 | 2.22e-12 | 182 |
GO:000734617 | Skin | cSCC | regulation of mitotic cell cycle | 192/4864 | 457/18723 | 3.47e-14 | 2.31e-12 | 192 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0002014 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123023 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062023 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0002015 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123033 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062033 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0120010 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120011 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120021 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa006208 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002010 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa012304 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120031 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa0062011 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002011 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa0123011 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120041 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
hsa0002021 | Liver | HCC | Citrate cycle (TCA cycle) | 28/4020 | 30/8465 | 1.08e-07 | 1.44e-06 | 8.02e-07 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PC | SNV | Missense_Mutation | novel | c.1378N>A | p.Ala460Thr | p.A460T | P11498 | protein_coding | deleterious(0.01) | benign(0.108) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | novel | c.1726N>G | p.Ser576Ala | p.S576A | P11498 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
PC | SNV | Missense_Mutation | | c.619N>C | p.Val207Leu | p.V207L | P11498 | protein_coding | deleterious(0.01) | possibly_damaging(0.822) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | | c.584C>T | p.Ala195Val | p.A195V | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | rs119103242 | c.1748N>A | p.Arg583His | p.R583H | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1217G>A | p.Arg406His | p.R406H | P11498 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.730N>T | p.His244Tyr | p.H244Y | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1848N>A | p.Met616Ile | p.M616I | P11498 | protein_coding | deleterious(0.01) | benign(0.059) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD |
PC | SNV | Missense_Mutation | novel | c.151N>A | p.Arg51Ser | p.R51S | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A6SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | aromatase | SD |
PC | SNV | Missense_Mutation | | c.2395N>A | p.Asp799Asn | p.D799N | P11498 | protein_coding | tolerated(0.18) | probably_damaging(0.967) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |